Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTX vs PTN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Captures Overall Composite Edge (53.5 HOLD vs 31.5 SELL), While PTN Leads 4–2 on Growth & Valuation Pillars

ENTX Overall Winner 6-Pillar Tally: ENTX 2 – 4 PTN Matrix Metrics: ENTX 7 – 3 PTN

As of Nov 16, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (53.5/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 7–3 (led by Profitability & Quality, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. ENTX trades at $3.02 (N/M Forward P/E, 0.0% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin).

  • Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. PTN 31.5/100 SELL) and 1.07β · 46% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.5); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs PTN
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 46% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.5 · SMA20: $3.09 · SMA50: $2.90
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07

6-Pillar Scorecard Institutional Category Breakdown (ENTX 2 – 4 PTN)

Columns: Metric · ENTX · PTN
1. Valuation Multiples PTN
Forward P/E N/M 42.9x
Trailing P/E N/M 42.9x
PEG Ratio N/M 1.62x
EV / Revenue N/M 0.1x
2. Growth & Scale PTN
Revenue Growth (YoY) -100.0% -80.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $13M
Market Cap $541.6M $11.1M
3. Profitability & Quality ENTX
Gross Margin N/A 6.2%
Operating Margin 0.0% -65.7%
Net Profit Margin 0.0% -63.5%
Return on Equity (ROE) -20.3% -877.5%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$16M -$15M
Cash Flow Margin N/A -113.6%
Net Cash / Leverage $265M Net Cash $9.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 113.8% (32nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity N/A 71.9% of Rev ($9.5M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (7) vs PTN (3)
Institutional Metric ENTX PTN Criterion Row Edge
Market Capitalization
Scale
$541.6M $11.1M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Forward P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY)
Growth
-100.0% -80.1% Higher Growth PTN
Operating Margin (TTM)
Profitability
0.0% -65.7% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% -63.5% Higher Margin ENTX
Return on Equity (ROE)
Capital Efficiency
-20.3% -877.5% Higher ROE ENTX
52-Week Range Position
Momentum
64% ($1–$4) 6% ($5–$31) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
1.07β · 46% Vol 0.87β · 106% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
53.5 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 6.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.62x PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$15M ($9.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +10.95 pp
ENTX: +12.69% · PTN: +1.74%
3M Horizon ENTX +46.22 pp
ENTX: +4.5% · PTN: -41.72%
6M Horizon ENTX +205.34 pp
ENTX: +145.53% · PTN: -59.81%
1Y Horizon ENTX +53.51 pp
ENTX: +10.22% · PTN: -43.29%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue PTN Revenue ENTX Op. Margin PTN Op. Margin Margin Leader
FY2019 N/A $60M N/A 59.3% PTN
FY2020 $0M $0M -3059.7% -20007.6% ENTX
FY2021 $0M N/A -2139.6% N/A ENTX
FY2022 $0M $0M -9714.2% -2491.6% PTN
FY2023 N/A $0M N/A -668.7% PTN
FY2024 $0M $0M -5295.6% -501.0% PTN
FY2025 $0M N/A -27450.0% N/A ENTX
FY2026 N/A $10M N/A -65.7% PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
79d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs PTN Key Questions & Quantitative Answers

As of Nov 16, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (53.5/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 7–3 (led by Profitability & Quality, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. ENTX trades at $3.02 (N/M Forward P/E, 0.0% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. PTN 31.5/100 SELL) and 1.07β · 46% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.5); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTN leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), ENTX cumulative revenue shifted N/A while PTN shifted -83.3%. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.

PTN screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus PTN (-877.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.